RE:RE:San. Francisco Notes on Just RVXThanks SF for all you hard work in your diligent note taking at the conference, looking forward to the completion of your notes.
As a long term shareholder and holder of zenith epigenetics shares, I am interested in what ultimate value the board feels in how much a 12% royalty on RVX 208 would be in terms of dividend per share even for Zenith holders if the drug does eventually goes to market. You had mentioned in your notes that DM saidsomething like 25 million users would equate to $30, Billion per year, That alot of moola to zentih shareholders even with some dilution